01. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
02. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
